

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: Unknown
Gender: Unknown
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Paraneoplastic Reflexive Panel, CSF

ARUP test code 3004517

Paraneoplastic Abs (PCCA/ANNA) IgG, CSF **None Detected** (Ref Interval: None Detected)

ANNA-1, ANNA-2, PCCA-1 or PCCA-Tr(DNER) antibodies not detected. No further testing will be performed.

INTERPRETIVE INFORMATION: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CV2.1 Ab IgG Screen, CSF **Detected *** (Ref Interval: < 1:1)

CV2.1 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

INTERPRETIVE INFORMATION: CV2.1 IgG Ab with Reflex to Titer, CSF

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS.

SOX1 Antibody, IgG by Immunoblot, CSF **Negative** (Ref Interval: Negative)

INTERPRETIVE INFORMATION: SOX1 Antibody, IgG by Immunoblot, CSF

SOX1 antibody is detected in patients with Lambert-Eaton myasthenic syndrome (LEMS) and in patients with paraneoplastic cerebellar degeneration (PCD), paraneoplastic and nonparaneoplastic neuropathy. SOX1 antibody is associated with small cell lung cancer. A negative test result does not rule out a diagnosis of LEMS or other causes of paraneoplastic neurological syndrome.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS.

Amphiphysin Antibody, CSF **Positive *** (Ref Interval: Negative)

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION: Amphiphysin Antibody IgG, CSF

Amphiphysin antibody is present in about 5 percent of patients with stiff-person syndrome and is found variably in other causes of paraneoplastic neurological syndrome (PNS). Amphiphysin antibody is mainly associated with small-cell lung cancer and breast tumors.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CV2.1 Antibody Titer IgG, CSF (Reflex for 3002257 CV2.1 CSF - Not orderable by clients)
ARUP test code 3002258

CV2.1 Antibody IgG Titer by IFA, CSF

1:10 * (Ref Interval: < 1.1)

INTERPRETIVE INFORMATION: CV2.1 Antibody IgG Titer by IFA, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Paraneoplastic Abs (PCCA/ANNA) IgG, CSF	22-054-100355	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2.1 Ab IgG Screen, CSF	22-054-100355	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2.1 Antibody IgG Titer by IFA, CSF	22-054-100355	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SOX1 Antibody, IgG by Immunoblot, CSF	22-054-100355	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Amphiphysin Antibody, CSF	22-054-100355	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: